Asparlas (calaspargase pegol-mknl) for Leukemia | MyLeukemiaTeam

Connect with others who understand.

sign up Log in
About MyLeukemiaTeam
Powered By

Asparlas is a prescription drug approved by the Food and Drug Administration (FDA) to treat children and young adults up to 21 years old with acute lymphoblastic leukemia (ALL). Asparlas is also referred to by its drug name, calaspargase pegol-mknl.

Asparlas is a component of a chemotherapy regimen used to treat pediatric acute lymphoblastic leukemia. Asparlas is part of a class of drugs called antineoplastic agents that is believed to work by breaking down the molecule asparagine, which is needed for cancer cells to survive.

How do I take it?
Prescribing information states that Asparlas should be administered by a health care provider intravenously for one hour, no more often than once every 21 days.

Asparlas comes in the form of an intravenous infusion (IV).

Side effects
The FDA-approved label for Asparlas lists common side effects including elevated transaminase, increased bilirubin, pancreatitis, and abnormal clotting.

Rare but serious side effects listed for Asparlas include allergic reactions, swelling of the pancreas, blood clots, increased sugar in the blood, unusual bleeding and bruising, and abnormal liver function.

For more details about this treatment, visit:

Asparlas – Servier

Asparlas — RxList

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in